[go: up one dir, main page]

AR120440A1 - Agonistas del receptor npy2 - Google Patents

Agonistas del receptor npy2

Info

Publication number
AR120440A1
AR120440A1 ARP200103125A ARP200103125A AR120440A1 AR 120440 A1 AR120440 A1 AR 120440A1 AR P200103125 A ARP200103125 A AR P200103125A AR P200103125 A ARP200103125 A AR P200103125A AR 120440 A1 AR120440 A1 AR 120440A1
Authority
AR
Argentina
Prior art keywords
receptor agonists
analogs
npy2 receptor
npy2
pyy
Prior art date
Application number
ARP200103125A
Other languages
English (en)
Inventor
Peter Wilhelm Haebel
Albert Brennauer
Charlotte Stahl Madsen
Sren Ljungberg Pedersen
Stefan Peters
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR120440A1 publication Critical patent/AR120440A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2271—Neuropeptide Y

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Análogos de PYY que tienen alanina en la posición 4, lisina en la posición 7, QRY como el extremo del terminar C y un grupo de prolongación de semivida. Los análogos son solubles a alrededor de pH 6 y 7. También composiciones farmacéuticas que comprenden tales análogos de PYY y el uso médico de los análogos.
ARP200103125A 2019-11-11 2020-11-10 Agonistas del receptor npy2 AR120440A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19208394 2019-11-11

Publications (1)

Publication Number Publication Date
AR120440A1 true AR120440A1 (es) 2022-02-16

Family

ID=68531488

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200103125A AR120440A1 (es) 2019-11-11 2020-11-10 Agonistas del receptor npy2

Country Status (20)

Country Link
US (3) US20210139548A1 (es)
EP (1) EP4058047A1 (es)
JP (1) JP2023500895A (es)
KR (1) KR20220100925A (es)
CN (1) CN114641303A (es)
AR (1) AR120440A1 (es)
AU (1) AU2020384729A1 (es)
CA (1) CA3156452A1 (es)
CL (1) CL2022001227A1 (es)
CO (1) CO2022006046A2 (es)
CR (1) CR20220206A (es)
DO (1) DOP2022000097A (es)
EC (1) ECSP22037660A (es)
IL (1) IL292601A (es)
JO (1) JOP20220110A1 (es)
MX (1) MX2022005661A (es)
PE (1) PE20221168A1 (es)
PH (1) PH12022551101A1 (es)
TW (1) TWI864155B (es)
WO (1) WO2021094259A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4058047A1 (en) 2019-11-11 2022-09-21 Boehringer Ingelheim International GmbH Npy2 receptor agonists
KR20230045088A (ko) * 2020-08-07 2023-04-04 베링거 인겔하임 인터내셔날 게엠베하 가용성 npy2 수용체 작용제
CN119677527A (zh) 2022-08-18 2025-03-21 勃林格殷格翰国际有限公司 包含长效glp-1/胰高血糖素及npy2受体激动剂的组合疗法
AU2023410450A1 (en) * 2022-12-21 2025-06-19 Boehringer Ingelheim International Gmbh Glp1/gip/npy2 receptor triple agonists
WO2024225848A1 (ko) 2023-04-28 2024-10-31 주식회사 피노바이오 항체에 하나 이상의 약물-링커 접합체가 결합된 항체-약물 접합체 및 이의 제조방법

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2422806A3 (en) 2004-02-11 2012-06-13 Amylin Pharmaceuticals Inc. Hybrid polypeptides with selectable properties
MXPA06010347A (es) 2004-03-17 2007-06-19 7Tm Pharma As Agonistas de receptor selectivo de y2 para intervenciones terapeuticas.
MX2007006830A (es) 2004-12-13 2008-02-07 Amylin Pharmaceuticals Inc Porciones de la familia del polipeptido pancreatico, polipeptidos y metodos que comprenden las mismas.
CA2630649A1 (en) 2005-12-07 2007-06-14 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor-agonists
AU2008216265B2 (en) 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US7994122B2 (en) 2007-06-15 2011-08-09 Zealand Pharma A/S Glucagon analogues
BRPI0722276A2 (pt) 2007-11-14 2014-04-22 Amylin Pharmaceuticals Inc Métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade
FR2934058B1 (fr) 2008-07-15 2010-09-24 Centre Nat Rech Scient Dispositif de projection interferometrique a trois ouvertures pour produire une tache constituee de structures fines
EP2370462B1 (en) 2008-12-15 2014-07-16 Zealand Pharma A/S Glucagon analogues
KR20110126592A (ko) 2008-12-15 2011-11-23 질랜드 파마 에이/에스 글루카곤 유사체
AU2008365555B2 (en) 2008-12-15 2016-01-14 Zealand Pharma A/S Glucagon analogues
MX2011006320A (es) 2008-12-15 2011-09-22 Zealand Pharma As Analogos de glucagon.
AP3329A (en) 2009-07-13 2015-06-30 Zealand Pharma As Acylated glucagon analogues
JP2013505221A (ja) 2009-09-18 2013-02-14 ノヴォ ノルディスク アー／エス 長時間作用性ｙ２受容体アゴニスト
EP2498800A1 (en) 2009-11-13 2012-09-19 Novo Nordisk A/S Long-acting y2 receptor agonists
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
AU2011269430A1 (en) 2010-06-24 2013-01-10 Zealand Pharma A/S Glucagon analogues
CA2838884C (en) 2011-06-10 2022-11-29 Novo Nordisk A/S Amylin receptor agonists
HK1200369A1 (en) 2011-12-23 2015-10-09 Zealand Pharma A/S Glucagon analogues
WO2013164483A1 (en) 2012-05-03 2013-11-07 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
PE20151808A1 (es) 2013-05-02 2015-12-16 Glaxosmithkline Ip Dev Ltd Peptidos terapeuticos
AR097701A1 (es) 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
ES2688708T3 (es) 2013-10-17 2018-11-06 Zealand Pharma A/S Análogos de glucagón acilados
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
US10131702B2 (en) 2013-11-06 2018-11-20 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
NO3068796T3 (es) 2013-11-14 2018-06-30
US10583172B2 (en) * 2013-11-15 2020-03-10 Novo Nordisk A/S HPYY(1-36) having a beta-homoarginine substitution at position 35
AU2014350197B2 (en) * 2013-11-15 2018-10-04 Novo Nordisk A/S Selective PYY compounds and uses thereof
BR112017019378A2 (pt) 2015-03-18 2019-02-19 Zealand Pharma A/S análogos de amilina
PL3283507T3 (pl) 2015-04-16 2020-05-18 Zealand Pharma A/S Acylowany analog glukagonu
CN107849110B (zh) 2015-06-12 2021-11-26 诺和诺德股份有限公司 选择性pyy化合物及其用途
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
EA038544B1 (ru) 2015-12-31 2021-09-13 Ханми Фарм. Ко., Лтд. Тройной агонист рецепторов глюкагона/glp-1/gip
CN109414501A (zh) 2016-05-03 2019-03-01 斯克利普斯研究院 用于治疗神经退行性疾病的TrkB激动剂抗体
TWI784968B (zh) 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 澱粉素類似物
JOP20190095A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
TW201833131A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物
TW201833132A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為肽類ｇｌｐ１／升糖素／ｇｉｐ三重受體激動劑之新穎化合物
CN108289005B (zh) 2017-01-09 2021-06-29 中兴通讯股份有限公司 信令发送、接收方法及装置
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
GB201720188D0 (en) 2017-12-04 2018-01-17 Imperial Innovations Ltd Analogues of PYY
TW202535916A (zh) 2018-11-01 2025-09-16 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
EP4058047A1 (en) 2019-11-11 2022-09-21 Boehringer Ingelheim International GmbH Npy2 receptor agonists

Also Published As

Publication number Publication date
AU2020384729A1 (en) 2022-04-14
TWI864155B (zh) 2024-12-01
WO2021094259A1 (en) 2021-05-20
TW202134263A (zh) 2021-09-16
CN114641303A (zh) 2022-06-17
CA3156452A1 (en) 2021-05-20
ECSP22037660A (es) 2022-06-30
MX2022005661A (es) 2022-09-07
KR20220100925A (ko) 2022-07-18
JOP20220110A1 (ar) 2023-01-30
IL292601A (en) 2022-07-01
US20230340039A1 (en) 2023-10-26
CR20220206A (es) 2022-06-16
US20250002544A1 (en) 2025-01-02
CO2022006046A2 (es) 2022-05-20
PE20221168A1 (es) 2022-07-25
PH12022551101A1 (en) 2023-11-13
JP2023500895A (ja) 2023-01-11
CL2022001227A1 (es) 2023-02-03
US20210139548A1 (en) 2021-05-13
US12054525B2 (en) 2024-08-06
DOP2022000097A (es) 2022-06-15
EP4058047A1 (en) 2022-09-21

Similar Documents

Publication Publication Date Title
AR120440A1 (es) Agonistas del receptor npy2
CL2023000357A1 (es) Agonistas del receptor npy2 solubles
MX392572B (es) Compuestos del péptido yy (pyy) selectivos y sus usos.
MX2020006474A (es) Ligandos de peptidos biciclicos especificos para el receptor eph de tirosina quinasa a2 (epha2).
CL2019002270A1 (es) Conjugados de anticuerpo y fármaco anti-egfr. (divisional solicitud 201803527)
CL2019001129A1 (es) Compuestos del péptido tirosina tirosina cíclico con anticuerpo acoplado como moduladores de receptores de neuropéptido y.
NZ743487A (en) Controlled-release cnp agonists with increased nep stability
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
MX2016006053A (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
MX2017007458A (es) Derivados del factor 21 de crecimiento de fibroblastos (fgf21) y sus usos.
MX2018005715A (es) Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash.
CL2019003441A1 (es) Puestos de mic-1 y usos de estos.
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
EA202091095A1 (ru) Пероральная доставка пептидных аналогов glp-1
BR112022006297A2 (pt) Agonistas de receptor de npy2
EA202192475A1 (ru) Способ получения стабильных пептидных составов
EP3838924A4 (en) POLYPEPTIDE DELIVERY COMPOSITION
AR113966A1 (es) LIGANDOS PÉPTIDOS BICÍCLICOS ESPECÍFICOS PARA EphA2